# Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment

> **NCT06087120** · — · RECRUITING · sponsor: **Gene Solutions** · enrollment: 125 (estimated)

## Conditions studied

- Breast Cancer Female
- Stage II Breast Cancer
- Stage III Breast Cancer
- HER2-positive Breast Cancer
- Triple Negative Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06087120
- **Lead sponsor:** Gene Solutions
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-16
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-31
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06087120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06087120, "Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06087120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*